Edward Ball is a Hematology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 W Arbor Dr
San Diego, CA 921039001
Telephone
800-926-8273Provider last certified this registry record 17 Dec 2019.
Clinical trials
- Samples From Leukemia Patients and Their Donors to Identify Specific Antigens
Sponsor: PersImmune, Inc
- Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
Sponsor: University of California, San Diego
- Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
Sponsor: The Emmes Company, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Iovance Biotherapeutics, Inc.Program year20241 payment
- Janssen Biotech, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.8%Thalidomide Analog27.6%Revlimid55%Lenalidomide27%Pomalyst18%Part D<11 patientsKinase inhibitor6%Imbruvica50%Jakafi50%Part D<11 patients+ 1 more class in this area
Nervous system
21.9%Opioid Agonist13.7%Oxycontin40%Tramadol Hcl31%Oxycodone Hcl29%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator5.2%Zolpidem Tartrate100%Part D<11 patients+ 1 more class in this area
Dermatology
16.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor16.2%Acyclovir100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 1998–2011 per NIH RePORTER. The latest:
- Adoptive T-Cell Therapy for Acute Leukemia
University of California, San Diego
FY2011$310,970R21CA132277 - Adoptive T-Cell Therapy for Acute Leukemia
University of California, San Diego
FY2010$320,588R21CA132277 - CTLA-4 Blockade to Stimulate Allogeneic Graft vs Tumor
University of California, San Diego
FY2010$169,262U01HL069273
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Tait Shanafelt, MD
Palo Alto University
Robert Bast, MD
The University of Texas MD Anderson Cancer Center
Thomas Witzig, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”